bimekizumab
ucb pharmaceuticals
['bimekizumab', 'axspa']
il-17a/f inhibition with bimekizumab in active nr-axspa wk 16 asas40 vs pbo rapid improvement 47.7 vs 21.4% tnf naive 46.6 vs 22.9% tnfir 60 vs 11.8% wk 24 &gt;50% asdas &lt;2.1 improved mri serious teae 0.4%
deodhar abs0544 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach